Home Page

Amsterdam, the Netherlands, October 7, 2015 - uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced that it will be hosting an Investor Day and simultaneous webcast in New York City on October 15, 2015, starting at 8:30 a.m. uniQure management and invited guests will discuss the Company's strategy, clinical programs and uniQure's vision of how gene therapy will change the future of medicine.

Event

Speakers

• Jörn Aldag, Chief Executive Officer, uniQure
• Deya Corzo, M.D., Senior Vice President, Research and Development, Liver/Metabolism, uniQure
• Christian Meyer, M.D., Ph.D., Chief Medical Officer, uniQure
• Patrick Most, M.D., Managing Director, uniQure GmbH
• Harald Petry, Ph.D., Chief Scientific Officer, uniQure
• Charles W. Richard, M.D., Ph.D., Senior Vice President, Research and Development, Neuroscience, uniQure
• Chester B Whitley, Ph.D., M.D., Principal Investigator, Lysosomal Disease Network

Analysts and qualified investors who would like to register or learn more about the event should contact Blair Atkinson of MacDougall Biomedical Communications at +1 812 454 6257 or +1 781 235 3060 or batkinson@macbiocom.com . Registration is required as space is limited.

Webcast
To access the webcast, log on http://edge.media-server.com/m/p/nroin5kw or go to the "Events" section on the "Media" page of uniQure's website, at http://www.uniqure.com/news/calendar-of-events . A replay of the webcast will be available on uniQure's website for at least 30 days following the event.

About uniQure
uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with CNS, liver/metabolic and cardiovascular diseases. www.uniQure.com

uniQure:
Aicha Diba
Investor Relations
Direct: +31 20 240 6100
Main: +31 20 566 7394
a.diba@uniQure.com

Media inquiries:
Gretchen Schweitzer
MacDougall Biomedical Communications
Direct: +49 172 861 8540
Main: +49 89 2424 3494
gschweitzer@macbiocom.com